PD-L1检测方法在非小细胞肺癌的研究进展

详细信息    查看全文 | 推荐本文 |

英文篇名：Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer 作者：郭雪晶 ; 曹赫 ; 周建娅 ; 周建英 英文作者：Xuejing GUO;He CAO;Jianya ZHOU;Jianying ZHOU;Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University; 关键词：PD-L1 ; 非小细胞肺癌 ; 免疫组织化学技术 ; 酶联免疫吸附测定 英文关键词：PD-L1;;Non-small cell lung cancer;;Immunohistochemistry;;Enzyme-linked immunosorbent assay 中文刊名：FAIZ 英文刊名：Chinese Journal of Lung Cancer 机构：浙江大学医学院附属第一医院呼吸内科; 出版日期：2019-01-20 出版单位：中国肺癌杂志 年：2019 期：v.22 基金：国家自然科学基金项目(No.81672299)资助~~ 语种：中文; 页：FAIZ201901009 页数：5 CN：01 ISSN：12-1395/R 分类号：46-50

摘要

PD-1/PD-L1抑制剂在非小细胞肺癌(non-small cell lung cancer, NSCLC)一线和二线治疗中均占重要地位,为NSCLC治疗提供了新的策略。已有的临床试验表明有效检测PD-L1的表达是免疫抑制剂治疗的关键环节。然而,目前尚缺乏PD-L1检测的金标准。近几年国内外免疫组织化学技术(immunohistochemistry, IHC)和酶联免疫吸附测定(enzyme-linked immunosorbent assay, ELISA)不断创新,因而在PD-L1检测中有良好的应用前景。文章就PD-L1检测方法在NSCLC中的研究进展进行了总结和展望。
        PD-1/PD-L1 inhibitors play an important role in the first-line and second-line treatment of non-small cell lung cancer(NSCLC), indicating a new treatment strategy of NSCLC. Completed clinical trials have shown that effective detection of PD-L1 expression is the key to the use of immunosuppressive agents. However, the gold standard for PD-L1 detection has still lacked. In recent years, immunohistochemistry(IHC) and enzyme-linked immunosorbent assay(ELISA) have been continuously innovated, which accounts for good prospect in PD-L1 detection. The research progress of PD-L1 detection methods in NSCLC is summarized in this review.

引文

[1]Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67(1):7-30. doi:10.3322/caac.21387
    [2]Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers:a heterogeneous set of diseases. Nat Rev Cancer, 2014,14(8):535-546. doi:10.1038/nrc3775
    [3]Mery B, Guy J-B, Swalduz A, et al. The evolving locally-advanced non-small cell lung cancer landscape:Building on past evidence and experience. Crit Rev Oncol Hematol, 2015, 96(2):319-327. doi:10.1016/j.critrevonc.2015.05.020
    [4]Karachaliou N, Cao MG, Teixido C, et al. Understanding the function and dysfunction of the immune system in lung cancer:the role of immune checkpoints. Cancer Biol Med, 2015, 12(2):79-86.doi:10.7497/j.issn.2095-3941.2015.0029
    [5]Herbst R S, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-smallcell lung cancer(KEYNOTE-010):a randomized controlled trial. Lancet, 2016, 387(10027):1540-1550. doi:10.1016/s0140-6736(15)01281-7
    [6]Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al.Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC(KEYNOTE-024):a multicenter, international, randomized, openlabel phase 3 trial. Lancet Oncol, 2017, 18(12):1600-1609. doi:10.1016/s1470-2045(17)30690-3
    [7]Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 2015, 372(21):2018-2028. doi:10.1056/NEJMoa1501824
    [8]Ji YZ, Liu XL, Miao H. Level of soluble programmed deathligand 1 in pleural effusion of lung cancer patients and its clinical significance.JianYanYiXue, 2017, 32(2):99-103.[冀玉珍,刘晓良,淼侯.可溶性程序性死亡分子配体在肺癌胸腔积液中的水平及临床意义.检验医学,2017, 32(2):99-103.] doi:10.3969/j.issn.1673-8640.2017.02.007
    [9]Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature; 2014,515(7528):568-571. doi:10.1038/nature13954.
    [10]Heymann JJ, Bulman WA, Swinarski D, et al. PD-L1 expression in non-small cell lung carcinoma:Comparison among cytology, small biopsy, and surgical resection specimens. Cancer, 2017, 125(12):896-907. doi:10.1002/cncy.21937
    [11]Skov BG, Skov T. Paired Comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC22C3pharmDx. Appl Immunohistochem Mol Morphol, 201725(7):453-459. doi:10.1097/pai.0000000000000540
    [12]Sakakibara R, Inamura K, Tambo Y, et al. EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer. Clin Lung Cancer, 2017, 18(5):527-534.e1. doi:10.1016/j.cllc.2016.12.002
    [13]Ilie M, Szafer-Glusman E, Hofman V, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol, 2018, 29(1):193-199. doi:10.1093/annonc/mdx636
    [14]Zhou F, Moreira AL. Lung carcinoma predictive biomarker testing by immunoperoxidase stains in cytology and small biopsy specimens:advantages and limitations. Arch Pathol Lab Med, 2016,140(12):1331-1337. doi:10.5858/arpa.2016-0157-RA
    [15]Cree IA, Booton R, Cane P, et al. PD-L1 testing for lung cancer in the UK:recognizing the challenges for implementation.Histopathology, 2016, 69(2):177-186. doi:10.1111/his.12996
    [16]Herbst RS, Baas P, Perez-Gracia JL, et al. P2.41(also presentedas PD1.06):Pembrolizumab vs Docetaxel for Previously Treated NSCLC(KEYNOTE-010):Archival vs New Tumor Samples for PD-L1 Assessment:Track:Immunotherapy. J Thorac Oncol, 2016,11(10S):S242-S243. doi:10.1016/j.jtho.2016.08.112
    [17]Lloyd IE, Zhou W, Witt BL, et al. Characterization of PD-L1immunohistochemical expression in cell blocks with different specimen fixation and processing methods. Appl Immunohistochem Mol Morphol, 2017. doi:10.1097/pai.0000000000000572
    [18]Rimm DL, Han G, Taube JM, et al. A prospective,multi-institutional, pathologist-based assessment of 4immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. J AMA Oncol, 2017, 3(8):1051-1058. doi:10.1001/jamaoncol.2017.0013
    [19]Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol, 2016, 29(10):1165-1172. doi:10.1038/modpathol.2016.117
    [20]Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1immunohistochemistry assays for lung cancer:results from phase1 of the blueprint PD-LI IHC assay comparison project. J Thorac Oncol, 2017,12(2):208-222. doi:10.1016/j.jtho.2016.11.2228
    [21]Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res, 2017, 23(14):3585-3591. doi:10.1158/1078-0432.ccr-16-2375
    [22]Adam J, Le Stang N, Rouquette I, et al. Multicenter French harmonization study for PD-LI IHC testing in non-small cell lung cancer. Ann Oncol, 2018, 29(4):953-958. doi:10.1093/annonc/mdy014
    [23]Smith J, Robida MD, Acosta K, et al. Quantitative and qualitative characterization of two PD-L1 clones:SP263 and E1L3N. Diagn Pathol, 2016,11(1):44. doi:10.1186/s13000-016-0494-2
    [24]Wang Y, Da JP, Wang DW, et al. Quantitative study of PD-L1expression in lung adenocarcinoma by image analysis technology and its clinical significance. Zhongguo Ti Shi Xue Yu Tu Xiang Fen Xi, 2016, 21(1):221-228.[王也,笪冀平,王德文,等.应用图像分析技术定量检测肺腺癌中PD-L1的蛋白表达及其临床意义.中国体视学与图像分析,2016, 21(1):221-228.] doi:10.13505/j.1007-1482.2016.21.02.010
    [25]Chen Y, Wang Q, Shi B, et al. Development of a sandwich ELISA for evaluating soluble PD-L1(CD274)in human sera of different ages as well as supernatants of PD-L1+cell lines. Cytokine, 2011, 56(2):231-238. doi:10.1016/i.cyto.2011.06.004
    [26]Enninga EAL, Harrington SM,Creedon DJ, et al. Immune checkpoint molecules soluble program death ligand 1 and galectin-9are increased in pregnancy. Am J Reprod Immunol, 2018, 79(2).doi:10.1111/aji.12795
    [27]Takeuchi M, Doi T, Obayashi K, et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol Lett, 2018, 196:155-160. doi:10.1016/j.imlet.2018.01.007
    [28]Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest, 2014,94(1):107-116. doi:10.1038/labinvest.2013.130
    [29]Caldwell C Jr, Johnson CE, Balaji VN, et al. Identification and Validation of a PD-L1 binding peptide for determination of PDL1expression in tumors. Scientific Reports, 2017, 7(1):13682. doi:10.1038/s41598-017-10946-2
    [30]Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387(10030):1837-1846. doi:10.1016/s0140-6736(16)00587-0
    [31]Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC:Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer, 2017, 112:200-215. doi:10.1016/j.lungcan.2017.08.005
    [32]Mao Y, Li W, Chen K, et al. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget, 2015, 6(5):3452-3461. doi:10.18632/oncotarget.3097
    [33]Okuma Y, Hosomi Y, Nakahara Y, et al. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer, 2017, 104:1-6. doi:10.1016/j.lungcan. 2016.11.023
    [34]Zhao J, Zhang P, Wang J, et al. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine,2017,96(7):e6102.doi:10.1097/md.0000000000006102
    [35]Tseng YH, Ho HL, Lai CR, et al. PD-L1 Expression of tumor cells,macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion. J Thorac Oncol, 2018,13(3):447-453. doi:10.1016/j.jtho.2017.10.034